Drugs / Del-desiran
Del-desiran
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07008469 | Jul 2025 → Aug 2030 expected | myotonic dystrophy type 1 | Avidity Biosciences, Inc. | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06411288 | May 2024 → Aug 2026 overdue | myotonic dystrophy type 1 | Avidity Biosciences, Inc. | Active not recruiting | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-09-08 | Novartis Pharmaceuticals | Results Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1) novartis.com ↗
Evidence of clinical activity in secondary endpoints and exploratory analyses were observed. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-09-08 | Novartis Pharmaceuticals | Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1) novartis.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Del-desiran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06411288 ↗ |
| Known as | AOC 1001 | “Del-desiran (AOC 1001) will be administered seven times” NCT06411288 ↗1“Del-desiran (AOC 1001)” NCT07008469 ↗ |
| Known as | Delpacibart Etedesiran | “A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly...” NCT07008469 ↗ |
| Route | Intravenous | “Del-desiran will be administered by intravenous (IV) infusion.” NCT06411288 ↗ |